Soligenix, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2011. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Its revenue came primarily from NIH grants and licensing payments; it had no marketed products described in the filing.
Financial results and position
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $5.796 million | $0.861 million | $7.010 million | $1.641 million |
| Gross profit | $5.141 million | $0.081 million | $5.451 million | $0.239 million |
| Gross margin | 88.7% | 9.4% | 77.8% | 14.5% |
| Operating income (loss) | $2.203 million | ($1.739 million) | ($1.452 million) | ($5.455 million) |
| Net income (loss) | $2.205 million | ($1.734 million) | ($1.447 million) | ($5.447 million) |
The reported gross profit and Q3 net income largely reflect a $5.0 million upfront payment from Sigma-Tau for exclusive European commercialization rights to orBec. Excluding that license revenue, gross profit was $140,737 for Q3 and $451,014 for the nine-month period. Research and development expense was $2.342 million in Q3 and $5.229 million year to date; general and administrative expense was $595,021 and $1.674 million, respectively.
- Cash and liquidity: Cash and equivalents were $7.218 million at September 30, 2011, versus $7.452 million at December 31, 2010. Working capital was $6.257 million, up from $6.101 million.
- Cash flows: Nine-month operating cash use was $730,131, compared with $4.209 million in 2010. Investing cash use was $152,664; financing provided $649,356. Cash declined by $233,439.
- Debt: The balance sheet lists no debt; current liabilities were $1.414 million, principally accounts payable. Total assets were $8.915 million and shareholders’ equity was $7.501 million.
- Equity financing and potential dilution: The company issued 1.816 million shares through its Fusion equity facility for $355,000 and received $253,613 from option and warrant exercises. At quarter end, 26.34 million options and 54.16 million warrants were outstanding.
Material developments and comparison
- On September 15, 2011, an independent Data Safety Monitoring Board recommended stopping the confirmatory Phase 3 orBec trial for acute GI GVHD because interim results indicated it was highly unlikely to meet its efficacy endpoint. The data were still under analysis.
- The Sigma-Tau European license generated $5.0 million in upfront revenue. The amendment also provides for up to $11 million in additional milestone payments and a 40% royalty on European net sales, subject to the agreement’s terms and commercial success. The original North American agreement provides a 35% royalty and potential milestones.
- Year-to-date revenue increased $5.369 million from 2010, due to the Sigma-Tau payment and higher NIH grant activity. Nine-month net loss narrowed by $4.000 million, principally because of the license payment, partly offset by increased R&D costs.
- R&D expense rose 30% year over year for the nine-month period, including a $1.013 million sublicense fee paid in cash and stock and higher orBec trial activity. 2010 included a one-time $378,501 write-off related to the returned BT-VACC license.
Outlook, risks and contingencies
- Management estimated existing cash, including Sigma-Tau proceeds and grant-funded program proceeds, would fund anticipated working capital and capital expenditures into the second quarter of 2013. This is a forward-looking estimate, not a guarantee.
- Management expected approximately $4.7 million of R&D expenditures over the next 12 months before grant reimbursements: $1.8 million for BioTherapeutics and $2.9 million for Vaccines/BioDefense. Grant revenue was expected to substantially offset the latter and partially offset the orBec trial wind-down.
- The company reported approximately $6.8 million in active grant funding available for research through 2013 and beyond. It planned to seek further grants, reduce costs, pursue New Jersey NOL sales, and potentially raise equity; it cautioned that additional financing might not be available on favorable terms.
- Near-term program plans included analyzing the stopped orBec trial, completing and reporting SGX201 Phase 1/2 data (expected in the first half of 2012), and pursuing RiVax, vaccine thermostability work, and other oral BDP indications. These programs remain subject to clinical, regulatory, funding, and commercial risks.
- There was approximately $280,000 of commitment related to the stopped orBec trial’s electronic data-capture contract. Other licensing arrangements may require contingent milestones or royalties. Management said it would assess potential impairment of the orBec patent portfolio after its review of the Phase 3 results.
- The company disclosed substantial biopharmaceutical development and regulatory risks, including the prior FDA “not approvable” letter for orBec. Its tax-loss carryforwards may be substantially limited under Section 382, and the company maintained a full valuation allowance against deferred tax assets.
Investor verification points
- Review the final analysis and implications of the stopped orBec Phase 3 trial, including any effect on development plans, Sigma-Tau milestones, and impairment testing.
- Confirm the timing and conditions of remaining Sigma-Tau milestones and the treatment of the $5.0 million license payment in reported results.
- Track cash burn, grant reimbursements and availability, R&D spending, and whether management’s runway estimate or financing plans change.
- Assess potential dilution from outstanding options and warrants and any further use of equity to fund operations or pay vendors.
- Check the filing’s stated Q3 2010 net loss against its EPS note: the statements and MD&A report ($1.734 million), while the EPS note shows ($1.774 million), an apparent inconsistency.